On (b)(6) 2018, the complainant was diagnosed with a choroidal nevi/small melanoma in her right eye.Her nevi is in the area near the central vision and present a risk factor like having a subretinal fluid.The drs understood that an avastin eye injection treatment was the least invasive methodology to try to control the nevi fluid.The complainant started to get an avastin eye injection every 6-8 weeks and received in every visit the following eye checkups: dilated eye exam, optical coherence tomography (oct) and a photo of her retina.The complainant's last avastin eye injection was on (b)(6) 2019, and after a week she still had a discomfort in her vision like seeing a rounded shadow in front of her or blurry vision.Because she had previous experience with the procedure after the injection and never took her so long to recover her normal vision, she decided to schedule an appt with her ocular oncologist on (b)(6) 2019.The oncologist examined her and explained to her that she has a dot of silicone in her eye.Then he proceeded to explain that there was existing evidence that those pre-filled eye injection syringes sometimes have the silicone migrating away from the syringe and into the liquid avastin.The dr indicated he would contact the pharmaceutical about the concern, he also provided the complainant with the name of the pharmaceutic and the serial number of the product.The complainant stated that her dr indicated this was a compounding product.The complainant granted permission to share her contact info with the mfr.
|